BNP Paribas Asset Management
DYN icon

BNP Paribas Asset Management’s Dyne Therapeutics DYN Stock Holding History

BNP Paribas Asset Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.51M Sell
157,916
-6,971
-4% -$130K ﹤0.01% 986
2026
Q1 		$2.99M Sell
164,887
-805
-0.5% -$13.9K ﹤0.01% 984
2025
Q4 		$3.24M Buy
165,692
+164,846
+19,485% +$3.12M ﹤0.01% 945
2025
Q3 		$11K Buy
846
+214
+34% +$2.44K ﹤0.01% 1598
2025
Q2 		$6K Buy
+632
New +$6.96K ﹤0.01% 1924

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

BNP Paribas Asset Management's DYN Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Dyne Therapeutics (DYN) stake by 4.2% in Q2 2026, selling an estimated $130K and leaving 157,916 shares worth $3.51M. The position accounts for ﹤0.01% of the portfolio, ranked #986.

BNP Paribas Asset Management first reported a position in DYN in Q2 2025 and has held it in 5 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • BNP Paribas Asset Management held 157,916 shares of Dyne Therapeutics worth $3.51M as of Q2 2026.
  • BNP Paribas Asset Management sold 6,971 Dyne Therapeutics shares in Q2 2026, an estimated $130K.
  • Dyne Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #986 holding.
  • BNP Paribas Asset Management first reported a position in Dyne Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.